Zura Bio ( (ZURA) ) has provided an update.
Zura Bio Limited has submitted a protocol to the FDA for a Phase 2 study of tibulizumab, an investigational antibody targeting IL-17A and BAFF, for treating systemic sclerosis. This trial aims to address unmet needs by exploring tibulizumab’s potential to mitigate immune dysregulation and fibrosis, key drivers of the disease. The study will evaluate safety and efficacy in 80 participants and is expected to start in late 2024.
For detailed information about ZURA stock, go to TipRanks’ Stock Analysis page.
